Recent research suggests that a new approach could help even patients with advanced forms of fatty liver disease.

Researchers describe successful tumor removal through the use of immunotherapy and targeted radiation therapy (TARE), in a patient previously considered ineligible for the procedure.

Can-Fite BioPharma (CANF) announced a significant clinical development: the disappearance of episodes of decompensated liver cirrhosis ...

Innovative therapies and surgical techniques have the potential to transform liver cancer care. People with cirrhosis—a ...

Discover why combining simvastatin and rifaximin does not offer a clinically meaningful advantage in preventing severe ...

The recipient, a liver cirrhosis patient who has been recuperating well since the Jan 20 transplant, went back home on Monday in good health. When the doctors embarked on the transplant ...

At a three-day event, hepatology experts focused on improving patient outcomes, particularly in ICU care, while exploring ...

Metabolic dysfunction-associated steatohepatitis (MASH) significantly increases the risk of liver cirrhosis and ...

and establish whether HMB can indeed deliver real benefits for people with cirrhosis and those around them." Those leading the project also held meetings with patients diagnosed with liver ...

However, where it fell short was with respect to the failure at week 36 with the phase 2b SYMMETRY study, which used EFX to treat compensated cirrhosis patients ... 3 SYNCHRONY Real-World study ...

and real-time market insights. Among patients with baseline and week 96 biopsies (n=134), 39% of patients treated with 50mg EFX (n=46) experienced reversal of cirrhosis with no worsening of MASH ...